Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis
Clinical trial NCT07190391 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07190391
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-09-30
- Primary completion
- 2026-12-31
- Enrollment
- 425
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.